ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
June 23, 2022 | ICSs, NHS, healthcare
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
The Health and Care Act became law in April. But what, in practice, will actually change for industry, and which stakeholders will be the most important commercially? Here are some of the key players the newly reformed NHS.
- Integrated Care Systems
The new legislation formalises the structural changes that have already happened, and in particular gives statutory authority to the 42 new Integrated Care Systems (ICSs) within the new landscape. Covering a geographical footprint of around 1 to 3 million people, ICSs will now take on official responsibility for a single budget, and will need to fulfil a ‘triple aim’ duty in the new Act requiring them to “consider the effects of their decisions on the health and wellbeing of the population, quality of care, and the sustainable use of NHS resources”.
- Integrated Care Board
Each ICS will be led by an Integrated Care Board (ICB) made up of a Chief Executive, Chair, Finance Director, Medical Director and a Director of Nursing, as well as up to three non-executive directors and partner members representing local authorities, trust providers and general practice. The ICB will be responsible for allocating resource and setting the strategic priorities for their population via a five-year service plan.
- Integrated Care Partnership
To help them do so, Integrated Care Partnerships (ICPs) will be responsible for developing an integrated care strategy to inform these system-level plans. ICPs are made up of organisations across local authorities, the NHS and voluntary sector. Their purpose is to bring together organisations involved in health, social care and public health delivery to make shared decisions on behalf of the people they serve, with a particular focus on addressing health inequalities and improving population health.
- Provider Collaboratives, Primary Care Networks and Place-Based Partnerships
Beneath them, there are further networks and entities responsible for delivering integrated services at different levels within the ICS. Provider Collaboratives bring secondary care provider organisations together at an operational level to develop more integrated service plans across a system or multi-system footprint. Primary Care Networks (PCNs) play a similar role for general practice and other primary and community care organisations at a highly localised, “neighbourhood” level, working with local councils and charities. Place-Based Partnerships (PCPs), meanwhile, are coalitions of NHS organisations, PCNs, local authorities, voluntary and third sector organisations and community interest groups which develop integrated plans at the intermediate “place” level, which is often mapped against a local authority footprint.
- Clinical networks
NHS customers will also be increasingly networked and incentivised to act collectively in pursuit of system goals. Clinical networks, most typically organised by disease area of pathway, will therefore hold even greater influence and need to be carefully courted by commercial organisations. Here is a more detailed piece on why clinical networks are set to be “change-makers” in the new NHS and how to connect with them effectively.
- Area Prescribing Committees
Formulary decision-making is changing too. With CCGs gone, the area prescribing committees (APCs) that were effectively the CCGs ‘medicines management arm’ will now organise themselves at an ICS level. The picture isn’t uniform and in many cases is still evolving, so you may find, for instance, independent decision-making happening at place and neighbourhood level as they develop their own formularies and ways of interpreting overall ICS medicines guidelines to adapt to local care pathways and service nuances.
Conclusion
These reforms are set to profoundly change the way pharma engage with the NHS. The customer landscape will shift, bringing in a new cast list of influencers, and these customers will be moulded by a different corporate environment. Suppliers will need to revisit their stakeholder mapping and be able to make their case on multiple levels, being mindful of both the immediate operational pressures on NHS organisations and the longer-term strategic priorities they are working to within a given system.
Finally, as this excellent long-read from the Health Foundation makes clear, all ICSs are not created equal. Each will have its own starting position, with unique pressure points and limitations, and variable ways of working. Gathering local intelligence, and using it to drive brand planning and sales strategy in a targeted way, will therefore be key to negotiating the new stakeholder environment.
On 29 June, Wilmington Healthcare will host a live webinar describing the new ICS landscape and how to work more effectively with NHS partners in the reformed NHS. To register, visit https://wilmingtonhealthcare.com/live-webinar-going-live-the-ics-landscape/.
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...